000144697 001__ 144697
000144697 005__ 20240229123019.0
000144697 0247_ $$2doi$$a10.1002/ijc.32651
000144697 0247_ $$2pmid$$apmid:31465545
000144697 0247_ $$2ISSN$$a0020-7136
000144697 0247_ $$2ISSN$$a1097-0215
000144697 0247_ $$2altmetric$$aaltmetric:65693812
000144697 037__ $$aDKFZ-2019-02139
000144697 041__ $$aeng
000144697 082__ $$a610
000144697 1001_ $$00000-0001-7749-8423$$ade Rojas, Teresa$$b0
000144697 245__ $$aEORTC SPECTA-AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe.
000144697 260__ $$aBognor Regis$$bWiley-Liss$$c2020
000144697 3367_ $$2DRIVER$$aarticle
000144697 3367_ $$2DataCite$$aOutput Types/Journal article
000144697 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1595425895_12985
000144697 3367_ $$2BibTeX$$aARTICLE
000144697 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144697 3367_ $$00$$2EndNote$$aJournal Article
000144697 500__ $$a2020 Aug 15;147(4):1180-1184
000144697 520__ $$aFor most adolescent and young adult (AYA) cancers, age-specific molecular features are poorly understood. SPECTA, an academic translational research infrastructure for biomaterial collection, will explicitly recruit AYA patients and will therefore collect empirical data to bridge the molecular gap between pediatric and adult oncology. The initial pilot study, activated in Feb-2019 across Europe, will recruit 100 AYA patients (aged 12-29 years) with newly diagnosed or relapsed high-grade gliomas and high-grade bone and soft tissue sarcomas. The primary objective of the pilot is to determine feasibility and recruitment rates. Formalin-fixed tumor tissue and whole blood from study participants will be prospectively collected with clinical data and stored centrally at the Integrated BioBank of Luxembourg (IBBL). Whole exome sequencing (WES) of matched tumor and blood, and tumor RNA sequencing and DNA methylation profiling will be performed at the German Cancer Research Center (DKFZ), Heidelberg. Virtual central pathology review of scanned diagnostic slides will be undertaken by an international expert panel, and diagnostic material returned to the participating centers. A multidisciplinary molecular tumor board will release a clinically validated report to referring clinicians within 4-6 weeks after biopsy. SPECTA-AYA constitutes a major opportunity to gain knowledge about the tumor biology of this unique age group. It incorporates notable innovative aspects: AYA specificity, pan-European academic collaboration, centralized biobanking, comprehensive molecular profiling, and virtual central pathology review, among others. SPECTA-AYA will help untangle the tumor particularities of AYAs with cancer and aims to improve their access to novel drugs and personalized medicine. This article is protected by copyright. All rights reserved.
000144697 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000144697 588__ $$aDataset connected to CrossRef, PubMed,
000144697 7001_ $$aKasper, Bernd$$b1
000144697 7001_ $$aVan der Graaf, Winette$$b2
000144697 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan M$$b3$$udkfz
000144697 7001_ $$aBielle, Franck$$b4
000144697 7001_ $$aRibalta, Teresa$$b5
000144697 7001_ $$aShenjere, Patrick$$b6
000144697 7001_ $$aPreusser, Matthias$$b7
000144697 7001_ $$0P:(DE-He78)f0144d171d26dbedb67c9db1df35629d$$aFröhling, Stefan$$b8$$udkfz
000144697 7001_ $$aGolfinopoulos, Vassilis$$b9
000144697 7001_ $$aMorfouace, Marie$$b10
000144697 7001_ $$00000-0002-5138-0707$$aMcCabe, Martin G$$b11
000144697 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.32651$$gp. ijc.32651$$n4$$p1180-1184$$tInternational journal of cancer$$v147$$x1097-0215$$y2020
000144697 909CO $$ooai:inrepo02.dkfz.de:144697$$pVDB
000144697 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000144697 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f0144d171d26dbedb67c9db1df35629d$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000144697 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000144697 9141_ $$y2020
000144697 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000144697 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000144697 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000144697 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000144697 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2017
000144697 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000144697 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000144697 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000144697 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000144697 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000144697 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000144697 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2017
000144697 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000144697 9201_ $$0I:(DE-He78)B340-20160331$$kB340$$lTranslationale Medizinische Onkologie$$x1
000144697 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000144697 980__ $$ajournal
000144697 980__ $$aVDB
000144697 980__ $$aI:(DE-He78)B062-20160331
000144697 980__ $$aI:(DE-He78)B340-20160331
000144697 980__ $$aI:(DE-He78)HD01-20160331
000144697 980__ $$aUNRESTRICTED